New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
10:06 EDTACT, TEVA, JBT, PKG, IP, PNFP, CMA, CHK, CFR, PGR, NVO, ADTN, ABC, CCL, BKH, CNP, KMB, SJM, NTI, MUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Actavis (ACT) downgraded to Market Perform from Outperform at Wells Fargo... Adtran (ADTN) downgraded to Neutral from Buy at Mizuho... AmerisourceBergen (ABC) downgraded to Neutral from Buy at UBS... Black Hill (BKH) downgraded to Sector Perform from Outperform at RBC Capital... Carnival (CCL) downgraded to Neutral from Outperform at Exane BNP Paribas... CenterPoint Energy (CNP) downgraded to Underperform from Neutral at Credit Suisse... J.M. Smucker (SJM) downgraded to Sell from Neutral at Goldman... Kimberly Clark (KMB) downgraded to Sell from Neutral at Goldman... Northern Tier (NTI) downgraded to Hold from Buy at Dahlman Rose... Novo Nordisk (NVO) downgraded to Underweight from Neutral at JPMorgan... Progressive (PGR) downgraded to Underweight from Equal Weight at Evercore... Teva (TEVA) downgraded to Market Perform from Outperform at Wells Fargo... JBT Corporation (JBT) downgraded to Neutral from Buy at Sidoti... Packaging Corp. (PKG) downgraded to Underperform from Outperform at CLSA... International Paper (IP) downgraded to Outperform from Buy at CLSA... Pinnacle Financial (PNFP) downgraded to Market Perform from Outperform at Raymond James... Comerica (CMA) downgraded to Underperform from Market Perform at Raymond James... Cullen/Frost (CFR) downgraded to Underperform from Market Perform at Raymond James... Chesapeake (CHK) downgraded to Trim from Hold at Tudor Pickering... Micron (MU) downgraded to Negative from Neutral at Susquehanna.
News For ACT;ADTN;ABC;CCL;BKH;CNP;KMB;SJM;NTI;NVO;PGR;TEVA;JBT;PKG;IP;PNFP;CMA;CHK;CFR;MU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 9, 2014
12:28 EDTACTAllergan price target raised to $230 from $210 at BTIG
BTIG said it expected Allergan to beat the consensus forecast for Q3 EPS, but not by as much as it did, and the firm did not expect the company to raise its future EPS outlook yet again. BTIG feels the stock's move higher indicates Valeant (VRX) or Actavis (ACT) would need to bid above $200 if they hope to buy the company. BTIG maintains its Buy rating on Allergan and raised its price target on the stock to $230 from $210.
11:14 EDTACTAllergan raises outlook again as Valeant pursuit continues
Drug maker Allergan (AGN) this morning preannounced stronger than expected results and again raised its fiscal year profit guidance. The beat and raise results come after The Wall Street Journal reported on Tuesday that drug maker Valeant (VRX) and hedge fund Pershing Square intend to raise their previous bid for Allergan by $15 per share to about $191. Meanwhile, also on Tuesday, Reuters said that drug maker Actavis (ACT) plans to make a new merger offer to Allergan, and sources indicated to the news service that Allergan may be willing to consider an offer from Actavis if the bid is for more than $200 per share. WHAT'S NEW: Allergan estimated that its third quarter earnings per share would come in at $1.76-$1.78, versus analysts' consensus estimate of $1.48. The drug maker had previously provided Q3 EPS guidance of $1.44-$1.47. Allergan raised its fiscal 2014 EPS guidance to $6.20-$6.25 from $5.74-$5.80. Analysts' consensus estimate was $5.81. This is the fourth time that Allergan has raised its guidance this year. Allergan said that its markets have been strong around the world, while it is gaining market share in most categories. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that, in the wake of Allergan's guidance increase, the company's price to earnings multiple could expand to 22x its estimated 2016 earnings, up from its current multiple of 19x. In addition to the raised guidance, a potential accretive acquisition by Allergan and the possibility that it will be acquired make such an increase in the multiple "quite possible," Biegelsen contended. He kept an Outperform rating on the stock. WHAT'S NOTABLE: Allergan has reportedly held advanced talks about acquiring another company in the sector, Salix (SLXP), although CNBC's David Faber on October 2 reported that the talks between the two companies about a merger had "cooled considerably." PRICE ACTION: In late morning trading, Allergan rose fractionally to $191.06 while Valeant slid 1.5% to $124.08.
08:50 EDTACTAllergan shares have further upside, says Wells Fargo
Subscribe for More Information
October 8, 2014
11:42 EDTMUStocks with call strike movement; AA MU
Subscribe for More Information
10:00 EDTMUOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTADTNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ADTRAN (ADTN) upgraded to Buy from Neutral at Goldman... Applied Materials (AMAT) upgraded to Outperform from Underperform at CLSA... Bill Barrett (BBG) upgraded to Neutral from Underperform at Macquarie... CNOOC (CEO) upgraded to Buy from Hold at Jefferies... Calamos (CLMS) upgraded to Market Perform from Underperform at Keefe Bruyette... Calix (CALX) upgraded to Buy from Neutral at Goldman... Cimarex Energy (XEC) upgraded to Outperform from Neutral at Macquarie... Cogent (CCOI) upgraded to Outperform from Market Perform at Raymond James... Coty (COTY) upgraded to Neutral from Sell at B. Riley... Dassault Systemes (DASTY) upgraded to Equal Weight from Underweight at Barclays... EOG Resources (EOG) upgraded to Outperform from Neutral at Macquarie... Glu Mobile (GLUU) upgraded to Buy from Hold at Benchmark Co.... Goldcorp (GG) upgraded to Overweight from Neutral at HSBC... Goodrich Petroleum (GDP) upgraded to Neutral from Underperform at Macquarie... Greif (GEF) upgraded at Wells Fargo... PHH Corp. (PHH) upgraded to Outperform from Market Perform at Keefe Bruyette... Parsley Energy (PE) upgraded to Outperform from Neutral at Macquarie... Rent-A-Center (RCII) upgraded to Buy from Neutral at Northcoast... Royal Gold (RGLD) upgraded to Overweight from Underweight at HSBC... Rush Enterprises (RUSHA) upgraded to Strong Buy at Raymond James... Sanchez Energy (SN) upgraded to Outperform from Neutral at Macquarie... Springleaf (LEAF) upgraded to Outperform from Neutral at Macquarie... TC PipeLines (TCP) upgraded to Neutral from Underweight at JPMorgan... Tesco (TSCDY) upgraded to Neutral from Underweight at HSBC... Vocera (VCRA) upgraded to Outperform at FBR Capital.
08:42 EDTACTSalix shares should be bought on weakness, says Sterne Agee
After Reuters yesterday afternoon reported that Actavis (ACT) plans to make a new merger approach to Allergan (AGN), Sterne Agee believes that Salix's standalone value is $162. The firm expects the shares to reach that level following approval of its Xifaxan IBS-D drug after the February 2015 PDUFA date.
08:05 EDTTEVATeva initiates NDA submission to FDA for CEP-33237
Teva Pharmaceutical announced the initiation of a rolling New Drug Application submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties CEP-33237 as allowed for fast track designated products. Teva expects to complete the NDA submission by the end of 2014. Teva also announced positive results from a nasal Human Abuse Liability study which supports the NDA. The nasal HAL study found that in nondependent, recreational opioid users, abuse potential for crushed intranasal CEP-33237 was significantly lower than intranasal immediate-release hydrocodone. Teva has now completed positive HAL studies in the two most common routes of hydrocodone abuse, oral and intranasal. CEP-33237 demonstrated a safety profile in the Phase III study that is consistent with the known safety profile of hydrocodone and other opioid analgesic therapies. Adverse events reported in 5% or more of hydrocodone-treated patients during either the titration or double-blind treatment periods included nausea, constipation, vomiting, headache, somnolence and dizziness.
07:43 EDTMUMicron initiated with a Neutral at Ladenburg
Subscribe for More Information
06:47 EDTACT, TEVALawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link
06:23 EDTACTActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
06:08 EDTADTNADTRAN upgraded to Buy from Neutral at Goldman
Subscribe for More Information
October 7, 2014
15:21 EDTACTAllergan warms to sale as Actavis plans new approach, Reuters says
Subscribe for More Information
15:01 EDTACTAllergan up 1.5% following report on Actavis planned approach on merger
14:59 EDTACTActavis plans new approach to Allergan, Reuters reports
Subscribe for More Information
13:46 EDTCCLCarnival finalizes Netherlands land purchase, begin construction in 2015
Carnival Corporation finalized its land purchase in Almere, Netherlands, marking the official start of development for its state-of-the-art training facility that will serve 6,500 deck and technical officers from all nine of its global cruise brands each year. The centerpiece of the new campus will be a new and three-times-larger Center for Simulator Maritime Training, Carnival Corporation's world-class maritime training, professional development and research facility, already operating in Almere. Construction on the facility is expected to begin in 2015.
10:02 EDTIPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Air France-KLM (AFLYY) upgraded to Overweight from Underweight at JPMorgan... Alcobra (ADHD) upgraded to Outperform at FBR Capital... Alon USA Partners (ALDW) upgraded to Buy from Neutral at Citigroup... Becton Dickinson (BDX) upgraded to Buy from Hold at Stifel... CNOOC (CEO) upgraded at Bernstein... CTC Media (CTCM) upgraded to Buy from Hold at Deutsche Bank... CVR Refining (CVRR) upgraded to Buy from Neutral at Citigroup... CalAmp (CAMP) upgraded to Outperform from Neutral at Macquarie... China Unicom (CHU) upgraded to Overweight from Equal Weight at Barclays... Crown Holdings (CCK) upgraded at Macquarie... Dick's Sporting (DKS) upgraded to Buy from Neutral at Goldman... Fortuna Silver Mines (FSM) upgraded to Outperformer from Sector Performer at CIBC... Franco-Nevada (FNV) upgraded to Buy from Hold at TD Securities... Horsehead Holding (ZINC) upgraded to Outperform from Market Perform at FBR Capital... Ingersoll-Rand (IR) upgraded to Buy from Neutral at Goldman... IntercontinentalExchange (ICE) upgraded to Buy from Neutral at Citigroup... International Paper (IP) upgraded at BofA/Merrill... Leidos (LDOS) upgraded to Neutral from Underperform at Credit Suisse... Lennox (LII) upgraded to Positive from Neutral at Susquehanna... MGM Resorts (MGM) upgraded to Buy from Hold at Deutsche Bank... Natus Medical (BABY) upgraded to Outperform at William Blair... Noodles & Company (NDLS) upgraded to Buy from Hold at Jefferies... Phillips 66 (PSX) upgraded to Buy from Neutral at Citigroup... RockTenn (RKT) upgraded to Buy from Neutral at BofA/Merrill... Smith & Nephew (SNN) upgraded to Hold from Sell at Societe Generale... Sotheby's (BID) upgraded to Buy from Hold at Craig-Hallum... Sun Life Financial (SLF) upgraded to Overweight from Equal Weight at Barclays... WellCare (WCG) upgraded at Sterne Agee... Yamana Gold (AUY) upgraded to Neutral from Underweight at HSBC.
08:32 EDTKMBKimberly Clark raises 2014 share repurchase target in spin-off completion
Kimberly-Clark announced the record date, distribution date and distribution ratio for the previously announced tax-free spin-off of its health care business. The spin-off will form the new publicly traded company, Halyard Health. Kimberly-Clark also increased its 2014 share repurchase program to take into account expected proceeds as a result of the spin-off. Kimberly-Clark shareholders will receive one share of Halyard Health common stock for every eight shares of Kimberly-Clark common stock held as of the close of trading on Oct. 23, 2014, the record date for the spin-off. Kimberly-Clark shareholders will receive cash in lieu of any fractional shares. The spin-off is expected to be effective as of the end of the day on Oct. 31, 2014, the distribution date for the spin-off, with 100 percent of the shares of Halyard Health distributed to Kimberly-Clark shareholders. Before completion of the spin-off, Halyard Health expects to make a one-time cash payment to Kimberly-Clark. As a result, Kimberly-Clark is increasing its 2014 share repurchase target to $2B, up from its previous plan of $1.3 to $1.5 billion.
07:48 EDTACTSalix reinstated with a Buy at Jefferies
Subscribe for More Information
07:34 EDTIPInternational Paper upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded International Paper to Buy from Neutral. The firm upgraded shares based on expectations the company will attempt to convert part of the portfolio to a Master Limited Partnership, or MLP. Price target raised to $55 from $53.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use